Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04982796 · ClinicalTrials.gov registry record · Phase 1
Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder
A Phase 1 study of Amphetamine-Related Disorders, sponsored by Portland VA Research Foundation.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT04982796: Recruiting Phase 1 study of Amphetamine-Related Disorders, sponsored by Portland VA Research Foundation.
NCT04982796 is a Phase 1 study of Amphetamine-Related Disorders that is actively recruiting participants, run by Portland VA Research Foundation. The registered enrollment target is 30 participants, below the 86-participant average among 5 other Amphetamine-Related Disorders trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04982796, a Phase 1 study of Amphetamine-Related Disorders, is actively recruiting participants, sponsored by Portland VA Research Foundation.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a proof-of-concept randomized clinical trial of psilocybin-enhanced psychotherapy versus treatment-as-usual among individuals being treated for methamphetamine use disorder.
Primary Outcome
We will use a 7-point Likert scale to measure each participant's perceived benefit and perceived harm of the intervention.
Conditions Studied
Interventions
- DRUG Psilocybin
- BEHAVIORAL Treatment-as-usual
Study Locations (1)
Washington
- Portland VA Health Care System - Vancouver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-07-07 |
| Est. Completion | 2026-04-30 |
| Phase | Phase 1 |
What NCT04982796 shows while recruiting
NCT04982796 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 86-participant average among 5 other Amphetamine-Related Disorders trials with a reported enrollment target (65% lower).
The record links to 1 condition, with Amphetamine-Related Disorders appearing as the primary indexed condition, and to 2 interventions - of which Psilocybin is the first listed.
NCT04982796 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT04982796 about?
NCT04982796 is a clinical study titled "Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder". This is a proof-of-concept randomized clinical trial of psilocybin-enhanced psychotherapy versus treatment-as-usual among individuals being treated for methamphetamine use disorder.
What is the current status of trial NCT04982796?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2022-07-07. Estimated completion is 2026-04-30.
What conditions does trial NCT04982796 study?
This clinical trial studies the following conditions: Amphetamine-Related Disorders.
What interventions are being tested in trial NCT04982796?
The interventions under investigation include: Psilocybin (DRUG), Treatment-as-usual (BEHAVIORAL).
Who is sponsoring clinical trial NCT04982796?
This trial is sponsored by Portland VA Research Foundation, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04982796 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amphetamine-Related Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant Abuse
COMPLETED · Phase 1
-
Contingency Management for Methamphetamine Abstinence and HIV Post-Exposure Prophylaxis in Men Who Have Sex With Men
COMPLETED · Phase 2
-
Bupropion for the Treatment of Methamphetamine Dependence - 1
COMPLETED · Phase 2
-
Tyrosine for Methamphetamine Dependence - 1
COMPLETED · Phase 2
-
Extended-Release Naltrexone to Treat Methamphetamine Dependence in Men Who Have Sex With Men (MSM)
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI